Release Date: 2024-05-28

Metabolomics in Alzheimer’s Disease

Asuman Gedikbasi (Author)

Release Date: 2024-05-28

The accumulation of amyloid-beta (Aβ) and phosphorylated tau (p-tau) proteins are known contributors to Alzheimer’s Disease (AD) pathogenesis, yet pharmacological interventions targeting these proteins have not been effective, indicating the involvement of additional molecular factors. These factors include lipid dyshomeostasis, altered energy and glucose metabolism, disturbed mitochondrial activity, oxidative stress, dysregulated cellular trafficking, and changes [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inAlzheimer’s Disease From Molecular Mechanisms to Clinical Practices
First Page189
Last Page208
DOIhttps://doi.org/10.69860/nobel.9786053359166.9
ISBN978-605-335-916-6 (PDF)
LanguageENG
Page Count20
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

The accumulation of amyloid-beta (Aβ) and phosphorylated tau (p-tau) proteins are known contributors to Alzheimer’s Disease (AD) pathogenesis, yet pharmacological interventions targeting these proteins have not been effective, indicating the involvement of additional molecular factors. These factors include lipid dyshomeostasis, altered energy and glucose metabolism, disturbed mitochondrial activity, oxidative stress, dysregulated cellular trafficking, and changes in neurotransmitter levels. Metabolomics, which reflects changes downstream of genomic, transcriptomic, and proteomic alterations, provides a sensitive measure of overall health by detecting endogenous metabolites, the final products of biochemical reactions.The Human Metabolome Database (HMDB) contains over 221,000 metabolites, including both water-soluble and lipid-soluble compounds. Metabolomics includes the study of polar metabolites (e.g., amino acids, carbohydrates) and lipids, with lipidomics focusing on the complete array of lipid classes. Metabolites serve as indicators of biochemical pathway changes in AD, and integrating genetic, transcriptomic, metabolomic, and proteomic data helps identify specific alterations. Two primary analytical techniques in metabolomics are mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. MS is favored for its sensitivity, selectivity, and ability to analyze a wide range of metabolites. Liquid chromatography-mass spectrometry (LC-MS) is particularly effective for diverse metabolites, offering comprehensive exploration of the metabolome. This chapter presents a summary of the results obtained from studies in this field.

Asuman Gedikbasi (Author)
Professor, Istanbul Cerrahpasa University
https://orcid.org/0000-0001-7121-6077
3Asuman Gedikbaşı, MD,PhD. Asuman Gedikbasi obtained her medical degree from the Medical School of Atatürk University in 1999. She completed residency training and specialization in Clinical Biochemistry in 2004 at the T.C. Ministry of Health Haydarpasa Numune Training and Research Hospital. In 2013, she worked as a researcher at the ""Harvard Medical School Children’s Hospital Boston Biochemical Genetics and Laboratory Medicine"". She earned the title of Associate Professor in Clinical Biochemistry in 2015. Until 2018, she worked as the Head of the Biochemistry Laboratory at the T.C. Ministry of Health Bakırköy Training and Research Hospital. Dr. Gedikbaşı completed her PhD in Genetics in 2020 at Istanbul University Institute of Health Sciences. She is Professor of Clinical Biochemistry and Medical Genetics at the Faculty of Medicine, Istanbul University, and Chief of the Metabolism Laboratory at the same University Hospital. Her main research areas are diagnostic laboratory medicine, biomarkers in common and rare diseases, biochemical diagnosis of inherited metabolic diseases by advanced biochemical methods (GC/MS, LC/MSMS), and molecular research of monogenic and multifactorial genetic diseases. She has published 135 full papers, over 200 abstracts, and several book chapters. Her H index is 18 (Google Scholar) and 13 ( WoS).

  • Lista S, González-Domínguez R, López-Ortiz S, González-Domínguez Á, Menéndez H, Martín-Hernández J, et al. Integrative metabolomics science in Alzheimer’s disease: relevance and future perspectives. Ageing Res Rev. 2023;101987.

  • Milos T, Rojo D, Erjavec GN, Konjevod M, Tudor L, Vuic B, et al. Metabolic profiling of Alzheimer's disease: Untargeted metabolomics analysis of plasma samples. Prog Neuro-Psychopharmacol Biol Psychiatry. 2023; 127:110830.

  • Naudí A, Cabré R, Jové M, Ayala V, Gonzalo H, Portero-Otín M, et al. Lipidomics of human brain aging and Alzheimer's disease pathology. Int Rev Neurobiol. 2015; 122:133-189.

  • Horgusluoglu E, Neff R, Song WM, Wang M, Wang Q, Arnold M, et al. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimer's Dement. 2022; 18:1260-1278.

  • Neff RA, Wang M, Vatansever S, Guo L, Ming C, Wang Q, et al. Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets. Sci Adv. 2021;7: eabb5398.

  • Alawode DO, Heslegrave AJ, Ashton NJ, Karikari TK, Simrén J, Montoliu-Gaya L, et al. Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. J Intern Med. 2021; 290:583-601.

  • Wilkins JM, Trushina E. Application of metabolomics in Alzheimer’s disease. Front Neurol. 2018; 8:323079.

  • González-Domínguez R, Sayago A, Fernández-Recamales Á. High-throughput direct mass spectrometry-based metabolomics to characterize metabolite fingerprints associated with Alzheimer’s disease pathogenesis. Metabolites. 2018; 8:52.

  • Harrieder E-M, Kretschmer F, Böcker S, Witting M. Current state-of-the-art of separation methods used in LC-MS based metabolomics and lipidomics. J Chromatogr B. 2022; 1188:123069.

  • Wang B, Yao K, Hu Z. Advances in mass spectrometry-based single-cell metabolite analysis. TrAC Trends Anal Chem. 2023;117075.

  • Gao S, Zhou X, Yue M, Zhu S, Liu Q, Zhao X-E. Advances and perspectives in chemical isotope labeling-based mass spectrometry methods for metabolome and exposome analysis. TrAC Trends Anal Chem. 2023;117022.

  • Ebbels TM, van der Hooft JJ, Chatelaine H, Broeckling C, Zamboni N, Hassoun S, Mathé EA. Recent advances in mass spectrometry-based computational metabolomics. Curr Opin Chem Biol. 2023; 74:102288.

  • Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016; 17:451-459.

  • Reveglia P, Paolillo C, Ferretti G, De Carlo A, Angiolillo A, Nasso R, et al. Challenges in LC–MS-based metabolomics for Alzheimer’s disease early detection: Targeted approaches versus untargeted approaches. Metabolomics. 2021; 17:78.

  • González-Domínguez R, Jáuregui O, Queipo-Ortuño MI, Andrés-Lacueva C. Characterization of the human exposome by a comprehensive and quantitative large-scale multianalyte metabolomics platform. Anal Chem. 2020; 92:13767-13775.

  • Li S. Computational methods and data analysis for metabolomics. New York, NY: Springer; 2020.

  • Forsberg EM, Huan T, Rinehart D, Benton HP, Warth B, Hilmers B, Siuzdak G. Data processing, multi-omic pathway mapping, and metabolite activity analysis using XCMS Online. Nat Protoc. 2018; 13:633-651.

  • Howell A, Yaros C. Downloading and Analysis of Metabolomic and Lipidomic Data from Metabolomics Workbench Using MetaboAnalyst 5.0, in Lipidomics: Methods and Protocols. New York, NY: Springer; 2023. p. 313-321.

  • Chen Y, Li E-M, Xu L-Y. Guide to metabolomics analysis: a bioinformatics workflow. Metabolites. 2022; 12:357.

  • Cuperlovic-Culf M, Badhwar A. Recent advances from metabolomics and lipidomics application in Alzheimer’s disease inspiring drug discovery. Expert Opin Drug Discov. 2020; 15:319-331.

  • Savonije K, Weaver DF. The role of tryptophan metabolism in Alzheimer’s disease. Brain Sci. 2023; 13:292.

  • Lin C-H, Lin Y-N, Lane H-Y, Chen C-J. The identification of a potential plasma metabolite marker for Alzheimer’s disease by LC-MS untargeted metabolomics. J Chromatogr B. 2023; 1222:123686.

  • Wu L, Han Y, Zheng Z, Peng G, Liu P, Yue S, et al. Altered gut microbial metabolites in amnestic mild cognitive impairment and Alzheimer’s disease: signals in host–microbe interplay. Nutrients. 2021; 13:228.

  • François M, Karpe AV, Liu J-W, Beale DJ, Hor M, Hecker J, et al. Multi-omics, an integrated approach to identify novel blood biomarkers of Alzheimer’s disease. Metabolites. 2022; 12:949.

  • Niedzwiecki MM, Walker DI, Howell JC, Watts KD, Jones DP, Miller GW, Hu WT. High‐resolution metabolomic profiling of Alzheimer’s disease in plasma. Ann Clin Transl Neurol. 2020; 7:36-45.

  • Hsieh C-F, Liu C-K, Lee C-T, Yu L-E, Wang J-Y. Acute glucose fluctuation impacts microglial activity, leading to inflammatory activation or self-degradation. Sci Rep. 2019; 9:840.

  • González A, Calfío C, Churruca M, Maccioni RB. Glucose metabolism and AD: Evidence for a potential diabetes type 3. Alzheimers Res Ther. 2022; 14:56.

  • Yang Z, Wang J, Chen J, Luo M, Xie Q, Rong Y, et al. High-resolution NMR metabolomics of patients with subjective cognitive decline plus: Perturbations in the metabolism of glucose and branched-chain amino acids. Neurobiol Dis. 2022; 171:105782.

  • Hajjar I, Liu C, Jones DP, Uppal K. Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD. Alzheimers Dement (Amst). 2020;12: e12064.

  • Bergau N, Maul S, Rujescu D, Simm A, Navarrete Santos A. Reduction of glycolysis intermediate concentrations in the cerebrospinal fluid of Alzheimer’s disease patients. Front Neurosci. 2019; 13:465696.

  • Huynh K, Martins RN, Meikle PJ. Lipidomic profiles in diabetes and dementia. J Alzheimers Dis. 2017; 59:433-444.

  • Kuo T-C, Tseng YJ. LipidPedia: a comprehensive lipid knowledgebase. Bioinformatics. 2018; 34:2982-2987.

  • Kao Y-C, Ho P-C, Tu Y-K, Jou I-M, Tsai K-J. Lipids and Alzheimer’s disease. Int J Mol Sci. 2020; 21:1505.

  • Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med. 2018;15: e1002482.

  • Panchal M, Gaudin M, Lazar AN, Salvati E, Rivals I, Ayciriex S, et al. Ceramides and sphingomyelinases in senile plaques. Neurobiol Dis. 2014; 65:193-201.

  • Mielke MM, Haughey NJ, Bandaru VVR, Schech S, Carrick R, Carlson MC, et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 2010; 6:378-385.

  • Dehghan A, Pinto RC, Karaman I, Huang J, Durainayagam BR, Ghanbari M, et al. Metabolome-wide association study on ABCA7 indicates a role of ceramide metabolism in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2022;119: e2206083119.

  • Hachem M, Nacir H. Emerging role of phospholipids and lysophospholipids for improving brain docosahexaenoic acid as potential preventive and therapeutic strategies for neurological diseases. Int J Mol Sci. 2022; 23:3969.

  • Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20:415-418.

  • Wood PL, Cebak JE, Woltjer RL. Diacylglycerols as biomarkers of sustained immune activation in Proteinopathies associated with dementia. Clin Chim Acta. 2018; 476:107-110.

  • Akyol S, Ugur Z, Yilmaz A, Ustun I, Gorti SKK, Oh K, et al. Lipid profiling of Alzheimer’s disease brain highlights enrichment in glycerol (phospho) lipid, and sphingolipid metabolism. Cells. 2021; 10:2591.

  • Babu AF, Koistinen VM, Turunen S, Solano-Aguilar G, Urban Jr JF, Zarei I, Hanhineva K. Identification and Distribution of Sterols, Bile Acids, and Acylcarnitines by LC-MS/MS in Humans, Mice, and Pigs—A Qualitative Analysis. Metabolites. 2022; 12:49.

  • Marksteiner J, Blasko I, Kemmler G, Koal T, Humpel C. Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer’s disease. Metabolomics. 2018; 14:1-10.

  • MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—an emerging role for gut microbiome. Alzheimers Dement. 2019; 15:76-92.

  • Sancesario GM, Bernardini S. Alzheimer's disease in the omics era. Clin Biochem. 2018; 59:9-16.

  • Hao L, Wang J, Page D, Asthana S, Zetterberg H, Carlsson C, et al. Comparative evaluation of MS-based metabolomics software and its application to preclinical Alzheimer’s disease. Sci Rep. 2018; 8:9291.

  • Yulug B, Altay O, Li X, Hanoglu L, Cankaya S, Lam S, et al. Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener. 2023; 12:4.

  • Liu F-C, Cheng M-L, Lo C-J, Hsu W-C, Lin G, Lin H-T. Exploring the aging process of cognitively healthy adults by analyzing cerebrospinal fluid metabolomics using liquid chromatography-tandem mass spectrometry. BMC Geriatr. 2023; 23:217.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!